These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22995972)

  • 61. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
    Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
    Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY; Arvanitis L; Bauer D; Rein W;
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Randomized, double-blind, placebo-controlled study of F17464, a preferential D
    Bitter I; Lieberman JA; Gaudoux F; Sokoloff P; Groc M; Chavda R; Delsol C; Barthe L; Brunner V; Fabre C; Fagard M; Montagne A; Tonner F
    Neuropsychopharmacology; 2019 Oct; 44(11):1917-1924. PubMed ID: 30822774
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.
    te Beek ET; de Boer P; Moerland M; Schmidt ME; Hoetjes NJ; Windhorst AD; van Berckel BN; Cohen AF; van Gerven JM; Lammertsma AA
    J Psychopharmacol; 2012 Aug; 26(8):1128-35. PubMed ID: 22290934
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risperidone in the treatment of schizophrenia.
    Bravo-Mehmedbasic A
    Med Arh; 2011; 65(6):345-7. PubMed ID: 22299296
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
    Casey DE; Daniel DG; Tamminga C; Kane JM; Tran-Johnson T; Wozniak P; Abi-Saab W; Baker J; Redden L; Greco N; Saltarelli M
    Neuropsychopharmacology; 2009 Apr; 34(5):1330-8. PubMed ID: 19052541
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Investigational dopamine antagonists for the treatment of schizophrenia.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
    Stauffer VL; Case M; Kinon BJ; Conley R; Ascher-Svanum H; Kollack-Walker S; Kane J; McEvoy J; Lieberman J
    Psychiatry Res; 2011 May; 187(1-2):42-8. PubMed ID: 21168920
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.
    Kubo K; Fleischhacker WW; Suzuki T; Yasui-Furukori N; Mimura M; Uchida H
    Acta Psychiatr Scand; 2019 Feb; 139(2):108-116. PubMed ID: 30198163
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response.
    Geerts H; Spiros A; Roberts P; Twyman R; Alphs L; Grace AA
    PLoS One; 2012; 7(12):e49732. PubMed ID: 23251349
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
    Leucht S; Zhao J
    J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An early improvement threshold to predict response and remission in first-episode schizophrenia.
    Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M
    Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Analysis of early response to the antipsychotic treatment and related factors in acute schizophrenia patients].
    Sun MX; Ma J; Wang X; Yang YF; Li WW; Zhang Y; Zhao JY; Du YH; Zhang HX; Zhang D; Lü LX
    Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(31):2425-2430. PubMed ID: 28835042
    [No Abstract]   [Full Text] [Related]  

  • 78. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
    Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
    Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
    Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
    BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.
    Bhathena A; Wang Y; Kraft JB; Idler KB; Abel SJ; Holley-Shanks RR; Robieson WZ; Spear B; Redden L; Katz DA
    Transl Psychiatry; 2013 Apr; 3(4):e245. PubMed ID: 23571810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.